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Introduction
Personalized medicine implies a tailored approach to patients that
offers more effective therapy for each individual, reduces risks and
avoids unnecessary treatments or diagnostic interventions. Treat-
ment of patients with cardiovascular diseases (CVDs) has markedly
improved through the evaluation of new therapy concepts in large,
controlled trials thatprovideevidence-basedguidance.While this ap-
proach has, e.g. reduced morbidity and mortality in acute coronary
artery disease and extended significantly life expectancy in chronic
ischaemic heart disease and heart failure, there remains a high, and
increasing, burden of CVD. Conditions such as atrial fibrillation,
acute heart failure, or sudden cardiac death still cause unacceptable
morbidity and mortality in the population. Furthermore, patients
who survive acute cardiac events often require long-term treatment
for chronic conditions. The development and implementation of
a more personalized management offer potential to significantly
improve outcome.
Controlled trials by nature apply the same approach and therapy
to patients with the same disease entity, even if with different
disease stages and manifestations. Yet clinical cardiological practice
aims to take into account differences between individual patients
into therapeutic decisions. Initial concepts of personalized medicine
focused heavily on genetic markers, particularly in oncology, but
equally in CVD where genomics was the first marker which was
considered.1,2 This has yielded interesting insights for some areas,
such as unwanted drug effects,3 but this one-sided approach has lim-
itations and a more comprehensive strategy is needed.4 Application
of risk stratification based on clinical, biochemical, imaging, and/or
genomic markers is already used to tailor therapy, but remains frag-
mented and research often focuses on single aspects of personaliza-
tion.
Based on a workshop held by the European Society of Cardiology,
this report summarizes the current state of stratified cardiovascular
care and examines the available and required tools to progress
towards more personalized cardiovascular medicine. Actions are
proposed that are necessary to expand and implement personalized
medicine in CVDs and overcome potential hurdles.
State-of-the-art in cardiovascular
medicine
Evidence-based medicine provided
important advances in cardiovascular care
In recent yearsCVDhasbeen leading themedical field inmovingaway
from treatment defined by individual physicians to treatment based
on evidence and guidelines. Large randomized clinical trials (RCTs)
and population studies have identified the benefit of novel therapies
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such as b-blockers, ACE-inhibitors, anticoagulants, PCI and stents,5–8
defibrillators, and pacemakers.9 The evidence-based approach has
led to major reductions in mortality in acute coronary syndromes
and stroke10,11 in a time when progress in other areas has been much
slower.12 Recently, however, some limitations to the evidence-based
medicine have emerged. For example, it has been recognized that
this approach is driven by the enrolment criteria of the trials and
may not provide results that are applicable to other subgroups of
patients such as those excluded by the trial. For this reason, the
need for different approaches to investigate efficacy of therapies in
selected populations has promoted the concept of ‘personalized
medicine’ defined as the selection of diagnostic and therapeutic strat-
egies based on prospectively validated patient characteristics, inte-
grating clinical parameters, biochemical, usually blood-based
biomarkers, and genetic information.
The adoption of this broad definition of ‘personalized medicine’ is
rooted in the recognition that contemporary cardiovascular care is
already using components of individualized medicine. Assessment of an
individual based on an assembly of risk factors, which is converted
into risk scores (e.g. SCORE, GRACE,13 TIMI,14 CHA2DS2VASc,
15
MAGGIC16), is an important, first step towards individualization in
current cardiology practice which requires better implementa-
tion.17,18 The electrocardiogram is an important and immediately
available ‘point-of-care’ diagnostic tool that provides further invalu-
able information, e.g. in the detection of ST elevation myocardial in-
farction in patients with chest pain, arrhythmias such as atrial
fibrillation or ventricular tachycardias, but also information on
heart rate, QRS widening, PR, or QT interval. Further individualiza-
tion of care is based on biochemical markers such as elevated
serum troponins which guide an invasive treatment strategy in
patients with acute chest pain when clinical information is inte-
grated.19 On a similar line, BNP measurements can help differentiate
heart failure from non-cardiac causes of breathlessness,20 and tropo-
nin or D-dimer may be useful to further estimate risk in patients with
atrial fibrillation.21 Further individualization of therapy comes
through imaging. Echocardiography has become a first line tool
where, e.g. reduced left ventricular function guides therapy with,
e.g. ACE-inhibitors andb-blockers, or implantation of a defibrillator.6
In other patients, echocardiography identifies concomitant cardiac
diseases that alter treatment, e.g. cardiomyopathies or valvular
heart disease.22 Advanced imaging techniques based on CT and
MRI are current standard of care to guide cardiovascular interven-
tions, e.g. fractional flow reserve to decide on stent placement,23
or aortic valve area estimation for treatment of aortic stenosis.24
Unmet needs in the management of
cardiovascular diseases
Yet this approach seems to have exploited much of its applications
and its limitations are emerging. Implementation of guidelines and
outcome studies has uncovered that the diversity in the general
population precludes a ‘one size fits all’ approach to common clinical
conditions, and that the current stratification is insufficient.25 Exam-
ples are the need for optimizing the approach to women presenting
with chest pain, specific demands of the elderly, or the variation in
drug response, e.g. to anticoagulants. Possibly the best illustration
of the remaining needs are the unyielding/persistent high mortality
rates in patients with atrial fibrillation even when evidence-based
therapy is applied.26 While the reduction in novel drugs reaching
the market has been observed in several disease areas, it is parti-
cularly salient in CVD.27 High costs associated with the demands of
large RCT to demonstrate efficacy in the global population are one
of the factors that underlie the reduced investment in this market
segment. Better definition of patient subpopulations through
better personalized diagnosis in the framework of novel disease clas-
sifications can reduce cost and increase efficiency of clinical trials.
Subsequent personalized treatments targeting those who are most
likely to benefit from a novel therapy can help to reduce the risk of
treatment failure and cut unnecessary expenditures. Specific
markers may allow targeting new therapies to patients who would
benefit most.
A distinct scope in CVD
Advanced personalization of cardiovascular medicine can be seen as
acontinuumas it further integratesemerging technologies,molecular
markers, and genomic variants into the current practice of stratified
medicine. This novel approach should be introduced in a comprehen-
sive manner from diagnosis to risk stratification and management.
One of the challenges is integrating all markers in a network analysis,
as, e.g. now developed to identify key hubs for signalling pathway
control.28 Specifically in CVD functional and structural biomarkers
obtained non-invasively through advanced imaging, electrocardiog-
raphy, and integrated multi-parameter modelling [e.g. as done in
the FP7-funded physiome project (http://www.vph-noe.eu/)] will
be of major value.
Areas in need for personalized
management
Identifying individuals at risk
Simple risk scores such as SCORE or CHA2DSVA2Sc are advocated
by the ESC based on proven benefit.29 They are easy to implement
due to low cost and easy access but define broad categories and,
e.g., are poor in identifying the medium-risk population. Targeting
individuals at risk for primary prevention remains a goal in athero-
sclerosis and sudden death, but equally important are identification
of patients for secondary prevention, e.g. after first ischaemic
events, and of individuals needing intensified screening for early
disease detection. In these areas better stratification is needed that
identifies whom to treat, when to treat and the targets that represent
a modifiable risk. Recent developments have used cardiac imaging,
where, e.g., MRI, stress echocardiography, or CT angiogram allows
to exclude relevant coronary artery disease in patients at moderate
disease risk (Supplementary material online).
Improving response to existing therapy
The major road block for improving the response to existing, often
life-saving therapies in CVD is the poor classification of disease en-
tities. Typical examples are heart failure and atrial fibrillation where
disease classification has not progressed beyond symptoms and
poorly discriminatory clinical signs such as left ventricular function
or the ECG pattern of atrial fibrillation. The recent further success
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in the management of acute coronary syndromes, in contrast, was
only possible due to more careful classification of patients with
chest pain by troponin isoforms. There is a clear need for advanced
disease classification, reflecting specific disease biology, to better
guide personalized therapy.
Avoiding rare side-effects
Avoiding side-effects of therapy is another important goal in this
context which is guided by integrated information. A good example
illustrating the potency of integrating careful phenotyping and
genomic information is the prediction of a pro-arrhythmic response
to medication with action potential prolonging properties such
as antibiotics. This pro-arrhythmic response is specific to only a
small portion of patients who can be identified by combination of
information from ECG, clinical parameters, and possibly genetic
information.30–32
In summary, integration of biological markers for specific disease
processes has the potential to identify patients at risk for first
(often lethal) cardiovascular events, to allow to target therapies to
patients who are most likely to benefit, and to allow better prediction
of unwanted side-effects of therapy.
Existing and emerging approaches
Genomics in CVD
The genomic gold rush of the past decades has brought major
insights in the spectrum of the genetic contribution to CVD. ‘Clas-
sical’ genetic techniques and functional assessment of the gene
defect have identified arrhythmia mechanisms in the long QT syn-
drome and other inherited arrhythmic diseases.33 – 35 These insights
are now shaping ‘genotype-specific therapy’,36 providing a role
model for the future use of novel, genomic information in CVD
management.
Large-scale GWAS studies have identified a number of relevant
alleles in common chronic diseases such as coronary artery disease
or atrial fibrillation.37–44 The potential to identify new disease
mechanisms and approaches for individualized therapy based on
genotype has yet to be harvested. PCSK9 and PITX2 provide first
examples for the potential of ‘polygenic’ genetic predispositions in
common CVDs.
A new taxonomy: the case of heart failure
and atrial fibrillation
New disease classifications are needed that better reflect known
causes, as exemplified by these chronic diseases. First, imperfect
attempts have been made in this direction, e.g. by distinguishing
heart failure with and without reduced systolic left ventricular func-
tion,45– 47 or by more recent proposals to classify atrial fibrillation
basedonpathophysiology.48 Contemporarydiseaseclassificationcan
integrate and valorize detailed clinical, but also genetic, functional,
and imaging information. A close interaction between basic scientists
and clinicians is needed to allow integration of relevant pathophysio-
logical subtypes in such a classification while retaining clinical robust-
ness and applicability.
Imaging and functional studies to
personalize management
A particular strength in CVD is the development of non-invasive
imaging tools to evaluate both structure and function of heart
and vessels by ultrasound, computed tomography, magnetic reson-
ance imaging, and nuclear cardiology techniques. Several specific
diagnostic tools guide therapy in ischaemic heart disease and valve
replacement. Yet these are still ‘stand-alone’ imaging approaches.
Combining advanced imaging with molecular markers can further
refine taxonomy, with the potential for molecular imaging on the
horizon. In atrial fibrillation imaging of fibrosis in combination with
circulating markers is an example.
Blood-based biomarkers
A key problem is the extractionof informationon the myocardiumand
the vascular wall from venous blood. Concepts are being derived from
tissuesamplestudies,e.g. relyingonmRNAandmicroRNA.Circulating
miRNA may spill over from intercellular communication in vascular
wall remodelling–51 and provide diagnostic and therapeutic guid-
ance.52,53 A search for blood-based markers for cardiac pathologies
may also make use of microparticles, secreted proteins, circulating
monocytes, or markers for epigenetic regulation.54
Inherited cardiac diseases
Several familial, monogenic heart diseases such as hypertrophic
cardiomyopathy or the long QT syndromes have been well charac-
terized. The genetic defects have been reported, and disease
mechanisms have been described in suitable models. The clinical
impact of the underpinning molecular defects on diagnosis, risk
stratification, and management remains rather heterogeneous.55
Despite this progress, mechanism-based or genotype-specific pre-
vention of sudden death has yet to become clinical reality:56 The
long QT syndromes are the only example where the genetic
defect can inform prognosis and hence management at present.56
Only recently some studies have approached the field with a
more integrated ‘omics’ view to investigate the consequences on
the phenotype of polymorphisms in the coding regions of causative
genes and in other regulatory gene structures as well as the role
of gene–gene interaction to regulate protein expression. There
is expectation that these investigations will provide insights in
the identification of patients at a higher risk of life-threatening
arrhythmias.
Pharmacogenomics, i.e. the use of genetic markers to identify
patients at risk for adverse reactions to pharmacotherapy, has
been proposed for several cardiovascular therapeutics including
antithrombotic agents, antiarrhythmic drugs,2,57 or rhabdomyolysis
on statin therapy.58 Even though the evidence for genetically con-
ferred differences in the response, e.g., to oral anticoagulants is
good, controlled trials of genotype-informed dosing did not
improve therapy.59,60 The interaction of ambient and inherited
factors that often results in unexpected reactions to therapy may
be easier assessed using integrated functional biomarkers, e.g., clin-
ical profiles (as done in warfarin dosing schemes)orECG changes,30,61
on therapy.
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Next steps towards personalized
cardiovascular medicine
Collecting genomic and molecular
information and their clinical context
A critical bottleneck for (pharmaco)genomic research is the limited
access to DNA samples and data from RCTs. The EU can amend pro-
cedures and protocols to allow long-term follow-up of trial patients
and access to biomaterials to support the identification and validation
of new disease-related biomarkers in such cohorts. Such amend-
ments should also allow using other functional information, e.g.
ECG or imaging. Efforts should be supported to change public
opinion on genetic testing. Good communication between patients
and providers will be necessary to define and balance the ‘need to
know’ vs. ‘risk of knowledge’ and this will further require education
of researchers, health care providers, patients, regulators, and
other stake holders.
Integrating information across platforms
and technologies for a new taxonomy of
CVD
To understand pathophysiology, clinical, imaging, functional, molecu-
lar, genomic, and/or epigenetic markers need to be connected, and
further linked to outcomes. New disease classifications can identify
patients who will benefit from existing and new interventions and
guide better personalization of CVD management, as outlined
above for atrial fibrillation or heart failure. The emerging pheno-
type/genotype-specific therapy of patients with inherited channelo-
pathies provides first evidence for such a pathophysiologically
mediated translation into new therapeutic concepts.22,36 Such
Figure 1 A roadmap from current clinical to personalized cardiovascular medicine. The left two images illustrate the current practice, namely
using clinical parameters and risk factors as the basis for therapeutic decisions, recently enhanced by the use of cardiac or vascular imaging modalities.
A better understanding of the molecular disease mechanisms and markers that can identify specific mechanisms in patients—especially in the
common, chronic, and multifactorial cardiovascular diseases such as heart failure, atrial fibrillation, or coronary artery disease—is needed to
design new and better targeted therapies to reverse disease processes. This is exemplified by the schematic of a cardiomyocyte (third image,
top) and vessel wall and blood components (third image, bottom). Integrating these insights into the current practice of clinical and imaging-based
cardiovascular medicine, through the application of new biological markers and new disease classifications, will allow a personalized approach to
cardiovascular medicine in the near future.
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integration presents a formidable challenge to data storage, manage-
ment and analysis, IT capacity, and accessibility.
Adapting clinical trial design
Stratification of patients at enrolment, e.g. based on a new disease
classification, or by including biological markers for disease processes
in the inclusion criteria, can help to design focused, lean, and
affordable trials. Innovative statistics will be needed: addressing a
multiplicity of potential biomarkers, identifying reliable and valid
measurements, and other issues need prospective consideration.
A sound regulatory framework and
research support
The EU has an essential role in shaping a European environment that
is conducive to personalized medicine, including the framework for
clinical trials, access to data and human biosamples. Using existing
biosample collections is an opportunity to explore personalized
therapy in a post hoc, hypothesis-generating fashion. Continued col-
laboration and further implementation of a strong public–private
partnership between academia and research institutes, biotech and
SMEs, and large companies are essential in the development of
personalized medicine, and require policy support.
Person-centred cardiovascular medicine
in an era of personalization
Personalized medicine has been driven by biology and indeed will
need to remain driven by biology and pathophysiology, but it is essen-
tial to consider and include the patient in his social circle. When effi-
cacy suggests equipoise, a person-centred view that includes the
patient in the process of diagnosis and therapeutic management62,63
is at the core of personalized care. This implies considering environ-
mental and cultural influences (e.g. gender vs. sex-dependent modu-
lation of disease). In CVD, several examples highlight the need for
inclusion of factors beyond biology, such as gender-dependent bias
in diagnosis, the influence of personal care on heart failure out-
come. Towards patients, information and empathy need to go to-
gether, and including patients in the development of a personalized
track is essential.
Conclusions
There is strong need to develop the current stratified practice of
CVD management into a better personalized cardiovascular medi-
cine, within a broad framework of global patient care. Clinical infor-
mation obtained from history and physical examination, functional
and imaging studies, biochemical biomarkers, genetic/epigenetic
data, and pathophysiological insights into disease-driving processes
need to be integrated into a new taxonomy of CVDs to allow perso-
nalized disease management. This has the potential for major health
benefits for the population suffering from cardiovascular diseases
(Figure 1).
Supplementary material
Supplementary material is available at European Heart Journal online.
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